Bladder Cancer Treatment Drugs Market

Bladder Cancer Treatment Drugs Market Size and Share Analysis

The global bladder cancer treatment drugs market is expected to rise from US$3.79 Bn in 2024 to US$14.8 Bn by the end of 2033. The market is projected to expand at a CAGR of 15.9% during the forecast period from 2024 to 2033.

Attributes	Key Insights
Bladder Cancer Treatment Drugs Market Size (2024E)	US$3.79 Bn
Projected Market Value (2033F)	US$14.8 Bn
Global Market Growth Rate (CAGR 2024 to 2033)	15.9%
Historical Market Growth Rate (CAGR 2019 to 2023)	13%

Key Highlights of the Market

• Advances in genomic profiling and molecular diagnostics
• Expanding treatment landscape for non-muscle invasive bladder cancer
• Increasing recognition of the importance of holistic and patient-centric care
• Increasing focus on adjuvant and neoadjuvant therapy

Market Introduction and Trend Analysis

There are two types of bladder cancer. One type is where only the bladder lining is impacted by non-muscle invasive bladder cancer. It does not penetrate the innermost layer of the bladder or the deep layer of the bladder's muscles. This illness is known as superficial bladder cancer.

Muscle-invasive bladder cancer is the second type where the cancerous cells have migrated into or through the muscle layer of the bladder wall. There are numerous treatment options available, including chemotherapy, surgery, and radiotherapy.

Sales of bladder cancer treatment drugs accounted for 1.4% share of the global oncology medicines market in 2022.

Cancer cells may stop reproducing and developing when exposed to chemotherapy (cytotoxic) drugs, which may also result in tumors becoming smaller.

Drugs used to kill cancer cells are known as cytotoxic medicines or cytostatic). With the advancement of pharmacological therapy, the importance of cytotoxic medications in cancer treatment has marginally decreased.

Advancements in medical research and technology have led to the development of novel treatment modalities, particularly immunotherapy and targeted therapy.

Such innovative approaches have revolutionized the management of bladder cancer by offering more effective and targeted treatments, thereby driving demand for these drugs.

Rising incidences of bladder cancer worldwide is one of the important factors are fueling the demand for effective treatment options.

A few more crucial factors such as aging populations, environmental exposures to carcinogens, and lifestyle habits contribute to the increasing burden of bladder cancer.

As a result, pharmaceutical companies are investing in research and development to meet the growing need for innovative therapies, driving market growth.

Historic Growth and Course Ahead

The global market expanded at a CAGR of 13% from 2019 to 2023 mainly due to a boost in cancer research funding. As a result of increased financing for cancer research, the quality of life for cancer patients has improved significantly and patient survival rates have significantly risen.

The National Cancer Institute (NCI) offers funding for research projects in fields where the commercial sector lacks interest, including ground-breaking basic research and projects on cancer screening, prevention, and rare malignancies.

The National Institutes for Health (NIH) in the US is the largest public supporter of biomedical research in the entire globe. The United States is now a global leader in the development of cancer medicines and diagnostic techniques.

It is because of NIH-funded research that has spurred discoveries that businesses rely on to bring novel cancer medications to market.

• The Consolidated Appropriations Act of 2022 provided the National Cancer Institute (NCI) with US$ 6.9 billion, an increase of US$ 353 million over FY 2021. In April 2016, the U.S. government gave the National Cancer Institute (NCI) US$5.2 billion, a 5.3% increase from the prior year.

Clinical studies are carried out by the NCI on cancer patients whose prognosis requires several diagnoses. Companies are encouraged to perform more research on cancer diagnosis and therapy when there is more funding for the same.

• As per the CDC 2020 report, Cancer was the second-highest cause of mortality in the U.S. in 2020, behind heart disease. In 2020, almost 602,350 people died from cancer, including 284,619 women and 317,731 men. Cancer deaths per 100,000 persons declined from 196.5 in 2001 to 144.1 in 2020, a 27% decrease. A majority of cancer-related fatalities occur in low- and middle-income nations.

One-third of all fatalities are attributable to the primary behavioral and dietary risk factors for death such as high body mass index, inadequate intake of fruits and vegetables, lack of physical exercise, and excessive tobacco and alcohol consumption.

Cancer mortality rates are continuing to decrease as a result of screening for some cancers. These cancer types include include breast, cervical, colon, prostate, rectal and recently, lung cancer, the availability of combination therapies for many cancers and the use of chemotherapy after surgery for breast and colon cancer.

The global bladder cancer treatment drugs market is forecast to surge ahead at a CAGR of 15.9% during the forecast period from 2024 to 2033 due to the factors mentioned above.

Market Growth Drivers

Evolving Treatment Landscape for Bladder Cancer

The treatment landscape for bladder cancer has evolved significantly in recent years, with the introduction of new drugs and treatment approaches.

Immunotherapy agents such as immune checkpoint inhibitors have revolutionized the management of advanced and metastatic bladder cancer, offering durable responses and improved survival outcomes for some patients.

Targeted therapies that inhibit specific molecular pathways involved in bladder cancer growth and progression are also expanding treatment options for patients with specific biomarker profiles.

The development and approval of novel therapies, including immunotherapy agents, targeted therapies, and combination regimens, are reshaping the treatment landscape for bladder cancer.

Drugs such as immune checkpoint inhibitors (e.g., pembrolizumab, atezolizumab) have transformed the management of advanced and metastatic bladder cancer, offering durable responses and improved survival outcomes for some patients.

Advances in genomic profiling, molecular diagnostics, and biomarker testing enable personalized treatment approaches in bladder cancer.

Biomarker-driven therapy selection helps identify patients who are likely to respond to specific treatments, allowing for tailored treatment strategies and improved patient outcomes.

Personalized medicine approaches optimize treatment efficacy while minimizing the risk of adverse effects and treatment-related toxicities.

Factors Impeding the Market

High Costs of Drug Development, and Lack of Availability of Cancer Medications

Drug development is not easy since it takes a long time and costs a lot of money. As it typically takes 10 years from synthesis to approval and 88% of medications are refused, studying the drug to ascertain its efficacy and safety comes at a significant cost. Drug duplication is another obstacle to the market.

• The dearth of innovation in new cancer medications in 2014 resulted in 74% of the new medications created by nine of the top 10 pharmaceutical companies being identical to those created by their rivals.
• According to a PharmacoEconomics study article in 2019, estimates of the total average capitalized pre-market research and development expenses ranged widely, from US$ 161 million to US$ 4.54 billion (2019). Anti-cancer medication had the highest therapeutic area-specific projections ($944 million to $4.54 billion).

The fact that a majority of important cancer medications are not available in underdeveloped and emerging nations is one of the main issues restricting the growth of the worldwide market for pharmaceuticals to treat bladder cancer.

• According to a publication by NIH in 2020 on Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe, the United States, Germany, and the United Kingdom are the only countries where more than 40 of the 55 cancer medications that were originally approved between 2012 and 2016 are available.

A majority of the world's countries lack access to pharmaceuticals because their makers either failed to obtain regulatory permission, their manufacturers were waiting for the outcome of reimbursement negotiations before releasing the drug there.

Most new pharmaceutical markets allegedly have less than 20% of cancer medications available.

Several factors, including a deficient healthcare system, inadequate infrastructure, and additional obstacles such as fragmented diagnostic environments, and numerous logistical and financial challenges such as high costs, and difficult regulatory pathways, cause this.

• Less than 50% of the cancer medications listed on the WHO EML are available to patients in LMICs, which make up more than 45% of the global population, according to data published by NIH in November 2022 on Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa.

Future Opportunities for Bladder Cancer Treatment Drug Manufacturers

Switching to Molecularly Targeted Medications, or Immunotherapies

The idea of switching to molecularly targeted medications or immunotherapies instead of conventional chemotherapy, which has historically been the basis of first-line treatment for advanced malignancies, has many appeals. It is because they promise improved efficacy and enhanced quality of life.

• Although early leaders Bristol-Myers Squibb, Merck, and Roche have the most well-established immunotherapy drug portfolios, AstraZeneca and Ferring B.V. have remarkable portfolios of early checkpoint-based immunotherapy approaches. A majority of these pharmaceuticals are expected to generate sell-side income of roughly US$ 1 billion in a few years.

In the next ten years, some estimates claim that the market for immunotherapy as a whole might represent 30% to 40% of the market for oncology medicines. This prediction becomes realistic with each regulatory permission that leading businesses in this sector acquire.

Continuous Investments in Drug Development and Therapeutic Innovation

Investment in drug development allows companies to obtain patent protection and market exclusivity for their innovative therapies.

This provides market players with a competitive advantage by granting them exclusive rights to commercialize their products, hence protecting their investments and maximizing returns on investment.

Continued investment in drug development therapeutic innovation and novel drug targets, drug delivery systems, and therapeutic modalities holds promise for the discovery of transformative treatments for bladder cancer.

Opportunities exist for the development of next-generation drugs with improved efficacy, safety profiles, and mechanisms of action.

Category-wise Analysis

Non-Muscle-Invasive Bladder Cancer Type Holds a Significant Market Share

Category	CAGR through 2022
Non-Muscle-Invasive Bladder Cancer	14.8%

Drugs used for non-muscle-invasive bladder cancer generated revenue worth US$2.15 Bn in 2022, with the segment projected to expand at a CAGR of 14.8% during the forecast period. Segment growth is owing to the high rates of recurrence and risk of progression.

According to a 2019 article from the World Journal of Oncology, 70% to 75% of all cancers are non-muscle-invasive. This is the initial type before progressing to muscle invasion.

Healthcare professionals focus on destroying cancer before it penetrates the muscles; hence the higher adoption.

Low-Grade Bladder Cancer Grade Creates Highest Demand

Category	Market Share in 2022
Low-Grade Bladder Cancer	69.8%

Low-grade bladder cancer accounted for a market revenue share of 69.8% in 2022. Low-grade bladder cancers are mostly on the bladder surface, rarely spread or metastasize.

These cancers also have a lower risk of recurrence after treatment. When tumors have been surgically removed, drug cleansing of the bladder may lower the likelihood of cancer returning.

Region-wise Analysis

The US Stands Out with over 43% Market Share

Country	Market Share in 2022
The United States	43%

Bladder cancer is the most commonly diagnosed cancer in North America. The increasing cases of bladder cancer is fueling the demand for efficient treatment options, hence driving the market growth.

Another significant factor including increasing healthcare expenditure in North America with improved access to healthcare is facilitating the advanced treatment options uptake for bladder cancer, contributing to the market growth.  

The US emerges as a large market for bladder cancer treatment drugs due to the high spending on cancer-related medical treatment in the country.

The US exhibited 43% share of the global market in 2022. Increasing cancer treatment spending is the key driver for the market growth. 

• Spending on cancer-related medical treatment in the United States was US$ 183 billion in 2015. By 2030, this amount is predicted to increase to US$ 246 billion, a 34% increase.
• In 2019, U.S. patients paid an estimated US$ 16.2 billion out-of-pocket for cancer care and lost close to US$ 5 billion in productivity, according to a yearly report by researchers at the CDC, the National Cancer Institute, the American Cancer Society, and the North American Association of Central Cancer Registries.

Europe Benefits from Increasing Cases of Bladder Cancer

Europe has also been witnessing a rise in the incidence and prevalence of bladder cancer like in North America. This trend is driving the demand for effective treatment drugs in the region.

The UK market for bladder cancer treatment drugs is evolving due to the expansion of cancer therapy options available in the country.

Immunotherapy and targeted therapies have gained traction in Europe with viable treatment options for bladder cancer. Drugs such as immune checkpoint inhibitors and targeted agents are being increasingly prescribed, contributing to market growth.

The UK accounted for 4.4% share of the global market for bladder cancer treatment drugs in 2022. Market growth in the country is attributed to the expansion of cancer therapy options.

There are numerous cutting-edge cancer treatments available all over the world. In addition, the drive for innovation in cancer treatments is being monitored by academic institutions, biopharmaceutical firms, and healthcare system stakeholders.

• The EMA (European Medicines Agency) approved twice as many novel Bladder Cancer Treatment Treatments (NAS) in 2019 as it did in 2020. 64 new drugs for the treatment of bladder cancer have been introduced globally in the last five years, bringing the 20-year total to 161. There were 37 new cancer medications introduced in the United Kingdom alone.

Competitive Landscape Analysis

The global market is consolidated with a limited number of key players.

Considering the competition from local players, key market players in the industry are focusing on acquiring such competitors to reach a large customer base, along with expanding into newer markets.

Manufacturers are also coming up with innovative products, most of which are currently in the pipeline.

Recent Industry Developments

July 2022

AstraZeneca announced an agreement for the acquisition of TeneoTwo and its clinical-stage T-cell engager, thereby strengthening its haematological cancer pipeline.

January 2021

Hikma confirmed the acquisition of GSK’s interests in entities and assets. It comprises of GSK’s pharmaceutical and consumer commercialization and manufacturing business in Egypt and the pharmaceutical division of GSK’s business in Tunisia.

Report Scope

Attributes	Details
Forecast Period	2024 to 2033
Historical Data Available for	2019 to 2023
Market Analysis	US$ Billion for Value
Key Regions Covered	North America Latin America Europe East Asia South Asia Oceania The Middle East & Africa
Key Countries Covered	The United States Canada Brazil Mexico Argentina Germany Italy France The United Kingdom Spain Poland Russia India Indonesia Malaysia Thailand China Japan South Korea Australia New Zealand GCC Countries South Africa Northern Africa Türkiye
Key Market Segments Covered	Cancer Type Cancer Grade Drug Type Distribution Channel Region
Key Companies Profiled	Pfizer Inc. Merck KgaA Merck & Co AstraZeneca PLC Roche Holding AG (Genentech) Astellas Pharma Inc. J&J (Janssen Biotech) Cipla Inc. Amneal Pharma, Bristol Myers Squibb Co. Dr Reddy’s Laboratories, Inc. Gilead Sciences Inc. Endo Pharma UroGen Pharma, Inc. Teva Pharmaceuticals (Actavis) Hikma Pharmaceuticals, Incyte
Customization & Pricing	Available upon request

Market Segmentation

By Cancer Type

• Non-Muscle-Invasive Bladder Cancer
• Muscle-Invasive Bladder Cancer

By Cancer Grade

• Low-Grade Bladder Cancer
• High-Grade Bladder Cancer

By Drug Type

• Immunotherapy
  • Bacillus Calmette-Guerin
  • Avelumab
  • Nivolumab
  • Pembrolizumab
  • Others
• Chemotherapy
  • Mitomycin C
  • Docetaxel
  • Paclitaxel
  • Cisplatin
  • Others
• Targeted Therapy
  • Erdafitinib
  • Enfortumab vedotin-ejfv
  • Sacituzumab govitecan
  • Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

By Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa

For report customisation and delivery information contact our sales representative.